The Enigma of Low-Dose Ketamine for Treatment of Opioid-Induced Hyperalgesia in the Setting of Psychosocial Suffering and Cancer-Associated Pain

References

• van den Beuken-van Everdingen MH, de Rijke JM, Kessels AG, et al. Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann Oncol. 2007;18(9):1437–1449. doi:10.1093/annonc/mdm056.
   PubMed Web of Science ®Google Scholar
• Chu LF, Angst MS, Clark D. Opioid-induced hyperalgesia in humans: molecular mechanisms and clinical considerations. Clin J Pain. 2008;24(6):479–496. doi:10.1097/AJP.0b013e31816b2f43.
   PubMed Web of Science ®Google Scholar
• Lee M, Silverman SM, Hansen H, Patel VB, Manchikanti L. A comprehensive review of opioid-induced hyperalgesia. Pain Physician 2011;14(2):145–161.
   PubMed Web of Science ®Google Scholar
• Juba KM, Wahler RG, Daron SM. Morphine and hydromorphone-induced hyperalgesia in a hospice patient. J Palliat Med. 2013;16(7):809–812. doi:10.1089/jpm.2011.0502.
   PubMed Web of Science ®Google Scholar
• Roeckel LA, Utard V, Reiss D, et al. Morphine-induced hyperalgesia involves mu opioid receptors and the metabolite morphine-3-glucuronide. Sci Rep 2017;7:10406.
   PubMed Web of Science ®Google Scholar
• Santonocito C, Noto A, Crimi C, Sanfilippo F. Remifentanil-induced postoperative hyperalgesia: current perspectives on mechanisms and therapeutic strategies. Lra. 2018;11:15–23. doi:10.2147/LRA.S143618.
   Google Scholar
• Kalaydjian A, Farah F, Cheng Y, Acquadro MA, Gerges FJ. Opioid induced hyperalgesia with intrathecal infusion of high dose fentanyl. Pain Pract 2018;19:222–223.
   PubMed Web of Science ®Google Scholar
• Lyons PJ, Rivosecchi RM, Nery JP, Kane-Gill SL. Fentanyl-induced hyperalgesia in acute pain management. J Pain Palliat Care Pharmacother. 2015;29(2):153–160. doi:10.3109/15360288.2015.1035835.
   PubMedGoogle Scholar
• Yi P, Pryzbylkowski P. Opioid induced hyperalgesia. Pain Med. 2015;16 Suppl 1:S32–S6. doi:10.1111/pme.12914.
   PubMed Web of Science ®Google Scholar
• McPherson ML, Walker KA, Davis MP, et al. Safe and appropriate use of methadone in hospice and palliative care: expert consensus white paper. J Pain Symptom Manage 2018;57(3):635–645.
   PubMed Web of Science ®Google Scholar
• Fine PG. Low-dose ketamine in the management of opioid nonresponsive terminal cancer pain. J Pain Symptom Manage 1999;17(4):296–300.
   PubMed Web of Science ®Google Scholar
• Lauretti GR, Lima IC, Reis MP, Prado WA, Pereira NL. Oral ketamine and transdermal nitroglycerin as analgesic adjuvants to oral morphine therapy for cancer pain management. Anesthesiology 1999;90(6):1528–1533.
   PubMed Web of Science ®Google Scholar
• Javery KB, Ussery TW, Steger HG, Colclough GW. Comparison of morphine and morphine with ketamine for postoperative analgesia. Can J Anaesth 1996;43(3):212–215. doi:10.1007/BF03011736.
   PubMed Web of Science ®Google Scholar
• Bell RF, Dahl JB, Moore RA, Kalso E. Perioperative ketamine for acute postoperative pain. Cochrane Database Syst Rev 2006; (3):CD004603.
   PubMedGoogle Scholar
• Joachimsson PO, Hedstrand U, Eklund A. Low-dose ketamine infusion for analgesia during postoperative ventilator treatment. Acta Anaesthesiol Scand.1986;30(8):697–702. doi:10.1111/j.1399-6576.1986.tb02505.x.
   PubMed Web of Science ®Google Scholar
• Stubhaug A, Breivik H, Eide PK, Kreunen M, Foss A. Mapping of punctuate hyperalgesia around a surgical incision demonstrates that ketamine is a powerful suppressor of central sensitization to pain following surgery. Acta Anaesthesiol Scand 1997;41(9):1124–1132.
   PubMed Web of Science ®Google Scholar
• Waldfogel JM, Nesbit S, Cohen SP, Dy SM. Successful treatment of opioid-refractory cancer pain with short-course, low-dose ketamine. J Pain Palliat Care Pharmacother. 2016;30(4):294–297. doi:10.1080/15360288.2016.1231732.
   PubMed Web of Science ®Google Scholar
• Ballard ED, Ionescu DF, Vande Voort JL, et al. Improvement in suicidal ideation after ketamine infusion: relationship to reductions in depression and anxiety. J Psychiatr Res. 2014;58:161–166. doi:10.1016/j.jpsychires.2014.07.027.
   PubMed Web of Science ®Google Scholar
• Berman RM, Cappiello A, Anand A, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 2000;47(4):351–354.
   PubMed Web of Science ®Google Scholar
• Irwin SA, Iglewicz A. Oral ketamine for the rapid treatment of depression and anxiety in patients receiving hospice care. J Palliat Med. 2010;13(7):903–908. doi:10.1089/jpm.2010.9808.
   PubMed Web of Science ®Google Scholar
• Zarate CA, Jr., Singh J, Manji HK. Cellular plasticity cascades: targets for the development of novel therapeutics for bipolar disorder. Biol Psychiatry.2006;59(11):1006–1020. doi:10.1016/j.biopsych.2005.10.021.
   PubMed Web of Science ®Google Scholar
• Vanderah TW, Gardell LR, Burgess SE, et al. Dynorphin promotes abnormal pain and spinal opioid antinociceptive tolerance. J Neurosci. 2000;20(18):7074–7079. doi:10.1523/JNEUROSCI.20-18-07074.2000.
   PubMed Web of Science ®Google Scholar
• Hutchinson MR, Zhang Y, Shridhar M, et al. Evidence that opioids may have toll-like receptor 4 and MD-2 effects. Brain Behav Immun. 2010;24(1):83–95. doi:10.1016/j.bbi.2009.08.004.
   PubMed Web of Science ®Google Scholar
• Lutz BM, Nia S, Xiong M, Tao YX, Bekker A. mTOR, a new potential target for chronic pain and opioid-induced tolerance and hyperalgesia. Mol Pain. 2015;11:32. doi:10.1186/s12990-015-0030-5.
   PubMed Web of Science ®Google Scholar
• Li X, Angst MS, Clark JD. A murine model of opioid-induced hyperalgesia. Brain Res Mol Brain Res 2001;86(1–2):56–62.
   PubMedGoogle Scholar
• Roeckel LA, Le Coz GM, Gaveriaux-Ruff C, Simonin F. Opioid-induced hyperalgesia: Cellular and molecular mechanisms. Neuroscience 2016;338:160–182. doi:10.1016/j.neuroscience.2016.06.029.
   PubMed Web of Science ®Google Scholar
• Seeburg PH, Burnashev N, Kohr G, et al. The NMDA receptor channel: molecular design of a coincidence detector. Recent Prog Horm Res 1995;50:19–34.
   PubMedGoogle Scholar
• Petrenko AB, Yamakura T, Baba H, Shimoji K. The role of N-methyl-D-aspartate (NMDA) receptors in pain: a review. Anesth Analg 2003;97(4):1108–1116.
   PubMed Web of Science ®Google Scholar
• Bartlett SE, Cramond T, Smith MT. The excitatory effects of morphine-3-glucuronide are attenuated by LY274614, a competitive NMDA receptor antagonist, and by midazolam, an agonist at the benzodiazepine site on the GABAA receptor complex. Life Sci 1994;54(10):687–694.
   PubMed Web of Science ®Google Scholar
• Zhao YL, Chen SR, Chen H, Pan HL. Chronic opioid potentiates presynaptic but impairs postsynaptic N-methyl-D-aspartic acid receptor activity in spinal cords: implications for opioid hyperalgesia and tolerance. J Biol Chem. 2012;287(30):25073–25085. doi:10.1074/jbc.M112.378737.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Munoz M, Sanchez-Blazquez P, Vicente-Sanchez A, Berrocoso E, Garzon J. The mu-opioid receptor and the NMDA receptor associate in PAG neurons: implications in pain control. Neuropsychopharmacol. 2012;37:338–349. doi:10.1038/npp.2011.155.
   PubMed Web of Science ®Google Scholar
• Celerier E, Rivat C, Jun Y, et al. Long-lasting hyperalgesia induced by fentanyl in rats: preventive effect of ketamine. Anesthesiology 2000;92:465–472. doi:10.1097/00000542-200002000-00029.
   PubMed Web of Science ®Google Scholar
• Larcher A, Laulin JP, Celerier E, Le Moal M, Simonnet G. Acute tolerance associated with a single opiate administration: involvement of N-methyl-D-aspartate-dependent pain facilitatory systems. Neuroscience 1998;84(2):583–589.
   PubMed Web of Science ®Google Scholar
• Ohnesorge H, Feng Z, Zitta K, et al. Influence of clonidine and ketamine on m-RNA expression in a model of opioid-induced hyperalgesia in mice. PLoS One. 2013;8(11):e79567 doi:10.1371/journal.pone.0079567.
   PubMed Web of Science ®Google Scholar
• Arout CA, Caldwell M, Rossi G, Kest B. Spinal and supraspinal N-methyl-D-aspartate and melanocortin-1 receptors contribute to a qualitative sex difference in morphine-induced hyperalgesia. Physiol Behav. 2015;147:364–372. doi:10.1016/j.physbeh.2015.05.006.
   PubMed Web of Science ®Google Scholar
• Allen CA, Ivester JR. Jr., Low-dose ketamine for postoperative pain management. J Perianesth Nurs. 2018;33(4):389–398. doi:10.1016/j.jopan.2016.12.009.
   PubMed Web of Science ®Google Scholar
• Bell RF, Eccleston C, Kalso EA. Ketamine as an adjuvant to opioids for cancer pain. Cochrane Database Syst Rev 2017;6:CD003351.
   PubMed Web of Science ®Google Scholar
• De Conno F, Groff L, Brunelli C, et al. Clinical experience with oral methadone administration in the treatment of pain in 196 advanced cancer patients. Jco. 1996;14(10):2836–2842. doi:10.1200/JCO.1996.14.10.2836.
   PubMed Web of Science ®Google Scholar
• De Kock M, Lavand'homme P, Waterloos H. Balanced analgesia' in the perioperative period: is there a place for ketamine? Pain 2001;92(3):373–380.
   PubMed Web of Science ®Google Scholar
• Gardner-Nix JS. Oral methadone for managing chronic nonmalignant pain. J Pain Symptom Manage 1996;11(5):321–328.
   PubMed Web of Science ®Google Scholar
• Maher DP, Chen L, Mao J. Intravenous ketamine infusions for neuropathic pain management: a promising therapy in need of optimization. Anesth Analg. 2017;124(2):661–674. doi:10.1213/ANE.0000000000001787.
   PubMed Web of Science ®Google Scholar
• Bosma RL, Cheng JC, Rogachov A, et al. Brain dynamics and temporal summation of pain predicts neuropathic pain relief from ketamine infusion. Anesthesiology 2018;129(5):1015–1024. doi:10.1097/ALN.0000000000002417.
   PubMed Web of Science ®Google Scholar
• Davis MP, Walsh D. Methadone for relief of cancer pain: a review of pharmacokinetics, pharmacodynamics, drug interactions and protocols of administration. Support Care Cancer. 2001;9(2):73–83. doi:10.1007/s005200000180.
   PubMed Web of Science ®Google Scholar
• Eap CB, Buclin T, Baumann P. Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. Clin Pharmacokinet. 2002;41(14):1153–1193. doi:10.2165/00003088-200241140-00003.
   PubMed Web of Science ®Google Scholar
• Peltoniemi MA, Hagelberg NM, Olkkola KT, Saari TI. Ketamine: a review of clinical pharmacokinetics and pharmacodynamics in anesthesia and pain therapy. Clin Pharmacokinet. 2016;55(9):1059–1077. doi:10.1007/s40262-016-0383-6.
   PubMed Web of Science ®Google Scholar
• Engelhardt T, Zaarour C, Naser B, et al. Intraoperative low-dose ketamine does not prevent a remifentanil-induced increase in morphine requirement after pediatric scoliosis surgery. Anesth Analg.2008;107(4):1170–1175. doi:10.1213/ane.0b013e318183919e.
   PubMed Web of Science ®Google Scholar
• Joly V, Richebe P, Guignard B, et al. Remifentanil-induced postoperative hyperalgesia and its prevention with small-dose ketamine. Anesthesiology 2005;103(1):147–155. doi:10.1097/00000542-200507000-00022.
   PubMed Web of Science ®Google Scholar
• Luginbuhl M, Gerber A, Schnider TW, et al. Modulation of remifentanil-induced analgesia, hyperalgesia, and tolerance by small-dose ketamine in humans. Anesth Analg 2003;96:726–732. table of contents.
   PubMed Web of Science ®Google Scholar
• Forero M, Chan PS, Restrepo-Garces CE. Successful reversal of hyperalgesia/myoclonus complex with low-dose ketamine infusion. Pain Pract.2012;12(2):154–158. doi:10.1111/j.1533-2500.2011.00475.x.
   PubMed Web of Science ®Google Scholar
• Winegarden J, Carr DB, Bradshaw YS. Intravenous ketamine for rapid opioid dose reduction, reversal of opioid-induced neurotoxicity, and pain control in terminal care: case report and literature review. Pain Med 2016;17:644–649.
   PubMed Web of Science ®Google Scholar
• Jansen KL. A review of the nonmedical use of ketamine: use, users and consequences. J Psychoactive Drugs. 2000;32(4):419–433. doi:10.1080/02791072.2000.10400244.
   PubMed Web of Science ®Google Scholar
• Wall J, Chauhan A. A case of opioid-induced hyperalgesia. J Pain Palliat Care Pharmacother.2018:1–3. doi:10.1080/15360288.2018.1546256.
   PubMed Web of Science ®Google Scholar
• Mercadante S, Arcuri E. Hyperalgesia and opioid switching. Am J Hosp Palliat Care. 2005;22(4):291–294. doi:10.1177/104990910502200411.
   PubMedGoogle Scholar
• Fine PG. Opioid insights:opioid-induced hyperalgesia and opioid rotation. J Pain Palliat Care Pharmacother.2004;18:75–79. doi:10.1080/J354v18n03_08.
   PubMedGoogle Scholar
• Koppert W, Sittl R, Scheuber K, et al. Differential modulation of remifentanil-induced analgesia and postinfusion hyperalgesia by S-ketamine and clonidine in humans. Anesthesiology 2003;99(1):152–159.
   PubMed Web of Science ®Google Scholar
• Patch Iii RK, Eldrige JS, Moeschler SM, Pingree MJ. Dexmedetomidine as part of a multimodal analgesic treatment regimen for opioid induced hyperalgesia in a patient with significant opioid tolerance. Case Rep Anesthesiol. 2017;2017:9876306. doi:10.1155/2017/9876306.
   PubMedGoogle Scholar
• Belgrade M, Hall S. Dexmedetomidine infusion for the management of opioid-induced hyperalgesia. Pain Med. 2010;11(12):1819–1826. doi:10.1111/j.1526-4637.2010.00973.x.
   PubMed Web of Science ®Google Scholar
• Yu Z, Wu W, Wu X, et al. Protective effects of dexmedetomidine combined with flurbiprofen axetil on remifentanil-induced hyperalgesia: a randomized controlled trial. Exp Ther Med.2016;12(4):2622–2628. doi:10.3892/etm.2016.3687.
   PubMed Web of Science ®Google Scholar
• Chan AK, Cheung CW, Chong YK. Alpha-2 agonists in acute pain management. Expert Opin Pharmacother. 2010;11(17):2849–2868. doi:10.1517/14656566.2010.511613.
   PubMed Web of Science ®Google Scholar
• Yuan Y, Sun Z, Chen Y, et al. Prevention of remifentanil induced postoperative hyperalgesia by dexmedetomidine via regulating the trafficking and function of spinal nmda receptors as well as PKC and CaMKII level in vivo and in vitro. PLoS One. 2017;12(2):e0171348. doi:10.1371/journal.pone.0171348.
   PubMed Web of Science ®Google Scholar
• Taiwo YO, Levine JD. Prostaglandins inhibit endogenous pain control mechanisms by blocking transmission at spinal noradrenergic synapses. J Neurosci. 1988;8(4):1346–1349. doi:10.1523/JNEUROSCI.08-04-01346.1988.
   PubMed Web of Science ®Google Scholar
• Ito S, Okuda-Ashitaka E, Minami T. Central and peripheral roles of prostaglandins in pain and their interactions with novel neuropeptides nociceptin and nocistatin. Neurosci Res 2001;41(4):299–332.
   PubMed Web of Science ®Google Scholar
• Baba H, Kohno T, Moore KA, Woolf CJ. Direct activation of rat spinal dorsal horn neurons by prostaglandin E2. J Neurosci 2001;21(5):1750–1756.
   PubMed Web of Science ®Google Scholar
• Minami T, Sugatani J, Sakimura K, et al. Absence of prostaglandin E2-induced hyperalgesia in NMDA receptor epsilon subunit knockout mice. Br J Pharmacol. 1997;120(8):1522–1526. doi:10.1038/sj.bjp.0701067.
   PubMed Web of Science ®Google Scholar
• Nishihara I, Minami T, Uda R, et al. Effect of NMDA receptor antagonists on prostaglandin E2-induced hyperalgesia in conscious mice. Brain Res 1995;677(1):138–144.
   PubMed Web of Science ®Google Scholar
• Troster A, Sittl R, Singler B, et al. Modulation of remifentanil-induced analgesia and postinfusion hyperalgesia by parecoxib in humans. Anesthesiology 2006;105(5):1016–1023.
   PubMed Web of Science ®Google Scholar
• Lenz H, Raeder J, Draegni T, et al. Effects of COX inhibition on experimental pain and hyperalgesia during and after remifentanil infusion in humans. Pain 2011;152(6):1289–1297. doi:10.1016/j.pain.2011.02.007.
   PubMed Web of Science ®Google Scholar